Repligen Corp.
http://www.repligen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repligen Corp.
Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
Market Brief: Orthobiologics Market Will See Modest Growth By 2024, Stimulated By Growth Factors
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Atoll GmBH
- C Technologies, Inc.
- Novozymes Biopharma Sweden AB
- TangenX Technology Corporation